Gastroenterology · Functional DyspepsiaTrial Updateclinicalmid-term

Trial Evaluates Dispepril® Efficacy in Functional Dyspepsia vs. Proton Pump Inhibitors

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/18/2026, 6:31:59 PM

Assessment confidence: 57% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing trial of Dispepril® could significantly alter treatment approaches for functional dyspepsia, a condition primarily managed with proton pump inhibitors (PPIs). If successful, this nutraceutical may disrupt the current market dynamics and influence prescribing behaviors. Regulatory context from MHRA (ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly) supports the near-term read. Assessment grounded in 17 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should monitor this trial closely as a successful outcome could lead to a shift in treatment paradigms for functional dyspepsia. The strongest clinical anchor is Assessment of the Efficacy of Highly Standardized Ginger and Perilla Nutraceutical (Dispepril®) in Improving Gastric and Intestinal Symptoms in Patients With Functional Dyspepsia (ClinicalTrials.gov), moderate corpus alignment. In Gastroenterology · Functional Dyspepsia, 2 regulatory and 6 competitive items passed relevance filtering for Gastroenterology.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer's Phase 3 Study of Tofacitinib in Pediatric Ulcerative Colitis Underway (Humanexa Signals) — entity match (gastroenterology). Secondary pressure from Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyo.

Regulatory Outlook

Regulatory risk is concentrated around ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly (MHRA). Regulatory pathway relevance (nda). Relevant agencies in corpus: MHRA, FDA. The trial results will inform the regulatory landscape for Dispepril®, influencing its approval and market entry as a viable alternative to PPIs.

Key Risks

Elevated medium regulatory exposure for Gastroenterology could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

A positive trial outcome could lead to a new treatment option, potentially capturing market share from established PPI therapies, thereby impacting revenue streams for companies involved in gastroenterology.
Bristol Myers Squibb document relevant to the signal.
Portfolio teams should monitor this trial closely as a successful outcome could lead to a shift in treatment paradigms for functional dyspepsia.

What Would Change This Assessment

This becomes more urgent if Key milestones include trial completion and publication of results, particularly regarding efficacy and safety outcomes.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly
MHRAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Assessment of the Efficacy of Highly Standardized Ginger and Perilla Nutraceutical (Dispepril®) in Improving Gastric and Intestinal Symptoms in Patients With Functional Dyspepsia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Left Atrial and Left Ventricular Structural and Functional Evaluation by CCTA for Predicting Post-Ablation Outcomes in Patients With Atrial Fibrillation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and Tolerance of THC 25: CBD 25 in Patients With Severe Pruritus: Multicenter, Double-blind, Randomized, Placebo-controlled Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Pfizer's Phase 3 Study of Tofacitinib in Pediatric Ulcerative Colitis Underway
Humanexa Signalshigh relevance
Entity match (gastroenterology)
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyo
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
OTAC Trial Evaluates Anti-COVID-19 Immunoglobulin in Outpatients
Humanexa Signalsmedium relevance
Moderate corpus alignment
Phase 3 Trial of Orelabrutinib in Secondary Progressive MS Underway
Humanexa Signalsmedium relevance
Moderate corpus alignment

Self-perceived learning outcomes of academic detailing discussing rational therapy with proton pump inhibitors among general practitioners in Norway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Discovery of azaindole/indole-fused pyrimidine tetracyclic scaffolds as novel potent CDK7 inhibitors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Gastroenterology

Commercial impact

medium

A positive trial outcome could lead to a new treatment option, potentially capturing market share from established PPI therapies, thereby impacting revenue streams for companies involved in gastroenterology.

Regulatory impact

medium

The trial results will inform the regulatory landscape for Dispepril®, influencing its approval and market entry as a viable alternative to PPIs.

What to watch

Key milestones include trial completion and publication of results, particularly regarding efficacy and safety outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.